Quad's vincristine sulfate
Par Pharmaceutical's subsidiary received FDA approval for the oncolytic agent in 1 mg/ml injectable in 1, 2, and 5 mg vials. Quad said it will launch the product, the first generic form of Lilly's Oncovin, the week of May 13. Par said the firm also received approval for a preservative-free form of vincristine.
You may also be interested in...
With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.
Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.
Starpharma's COVID-busting Viraleze antiviral nasal spray will soon be available across Europe, included the UK. But will it fall foul of local evidence requirements, for example in France, where the country's medicines agency has halted the sale of Pharma & Beauty (P&B) Group's COV-Defense spray until its efficacy against COVID has been confirmed by human-based studies?